Thank you for Subscribing to Life Science Review Weekly Brief
Synthetic biology technology has matured to a point where it can produce virtually anything competitively and sustainably. Businesses must learn syn-bio to create new products and processes, enhance existing ones, and decrease costs to remain competitive.
FREMONT, CA: Numerous commercially viable synthetic biological products have been created as alternatives to high-value commodities, particularly those depending on the petroleum supply chain and nonrenewable resources. Additionally, synthetic substitutes and replacements for compounds traditionally obtained from nature are gaining traction in research and business arenas.
Synthetic biology involves the construction of artificial systems that can perform beneficial tasks. Using the knowledge of enzyme chemistry, for instance, researchers can genetically encode a synthetic pathway within a DNA sequence. Once inside a bacterium, this DNA will force the organism to manufacture the desired chemical. Using an analogy, this is the equivalent of a reaction flask that creates all the catalysts and reagents for a given total synthesis at the precise point along the synthetic route where they are needed, performed in water using renewable materials and completed in less than a day.
Synthetic biology could indirectly aid conservation efforts by enabling the creation of artificial substitutes for commercial products that are typically derived from the wild. For instance, the horseshoe crab's blood is a crucial medicinal product used to detect bacterial contamination in medications. Unsustainable harvesting practices are driving the species to extinction on a worldwide scale. A synthetic alternative that could reduce the need to harvest endangered crabs has been developed. Similarly, synthetic microorganisms and microalgae capable of creating omega-3 oil alternatives could alleviate the strain on diminishing wild fish sources.
There are numerous. The desired products can be generated directly from raw materials such as glucose, carbon dioxide, and methane. Once the finest enzymes have been identified, they can be transferred between species; genome engineering can even be used to connect entire pathways.
Subcellular compartments can hold reactive and toxic intermediates, hence minimizing hazardous waste. And the final product can be expelled from the cell via natural secretion channels, eliminating the need for laborious purifications.
Researchers lack enzymes that can match every known organic chemistry reaction; therefore, synthetic biology cannot even begin to compete with the variety of molecules accessible through conventional methods. In addition, numerous economically significant compounds feature structural motifs that cannot be synthesized using current enzymatic chemistry. Many contemporary bioprocesses yield synthetic intermediates, which are subsequently isolated and refined in a laboratory of synthetic chemistry to produce the final product.
Life Technologies Offers a Comprehensive Vaccine Development Workflow
In both developing and industrialized nations, the demand for cost-effective vaccines to prevent infectious diseases is increasing. However, developing novel vaccines is a lengthy process, requiring the identification of antigens—such as weakened viruses, bacterial toxins, and other pathogens—and the creation, purification, and manufacture of immunogens that could be used to prevent or treat diseases.
Life Technologies has a history of vaccine development success. It provides the molecular engineering tools and services essential to sequence genetic information to formulate vaccines and other therapies more quickly and efficiently than current procedures, saving researchers time.
Due to synthetic biology, life technologies can develop, synthesize, test, and deploy antigens and variations with rapid results, high expression, and capacity. It also permits Life Technologies to design immunogens engineered for efficacy and high titer and produce quick assays for the immunogens' purification.